Application available by clicking on the link above or the “Scholarships” tab at the top of this page.
Posts belonging to Category Breaking News
David Tuller and Julie Rehmeyer have published an article in the New York Times about ME and the PACE trial. https://www.nytimes.com/2017/03/18/opinion/sunday/getting-it-wrong-on-chronic-fatigue-syndrome.html?smid=tw-share&_r=0
Available at Scholarships tab above
This is the season of giving. Tuesday is National Day of Giving! Be a part of #GivingTuesday – DONATE to NJME/CFSA! NJ/MECFSA is a 501(c)(3) non-profit organization. DONATE at http://www.njcfsa.org/donate/ If you prefer there is also https://www.gofundme.com/ArpitaSheth-MyME (funds also go directly to the organization
The 2016 Scholarships have been posted. Click on the “Scholarships” tab above. The Medical Scholarship winner and runner-up essays are at that site.
Simple Way to Assess Orthostatic Intolerance
Dr. Nancy Klimas’ ME/CFS Gene Study at Nova Southeast University is still seeking patient and healthy volunteers. If you are interested, you can send a message to Helpdesk@njmecfsa.org and we will forward it to the study. More information can be found at https://sharkmedia.nova.edu/m…/ME+CFS+Genes+Study/1_06vh90p0 This is a chance for both patients and healthy volunteers to participate.
Read about the encouraging results at: http://www.meaction.net/2016/09/09/members-of-congress-urge-nih-director-francis-collins-to-strengthen-biomedical-research-into-myalgic-encephalomyelitis-chronic-fatigue-syndrome/
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic First Product Approved for ME/CFS Indication Anywhere in the World. Ampligen Approved in Argentina – First in the World 2016-08-23
August is Membership Renewal Month Please support the work of NJME/CFSA. See information at the link below. 2016-08 Membership Renewal Request